Since TGF-β is involved in EMT, TGF-β-neutralizing antibodies and TGF-β receptor inhibitors have been employed in attempts to inhibit EMT, thereby reducing tumor metastasis and enhancing chemotherapy sensitivity [34], [35]. The gene discussed is TGFB1; the disease is neoplasm.